Dry eye – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:17:47 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Dry eye – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ianalumab-for-patients-with-active-sjogrens-syndrome/ Mon, 04 May 2026 07:52:39 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ianalumab-for-patients-with-active-sjogrens-syndrome/ This clinical trial is focused on studying the effects of a treatment for Sjögren’s syndrome, a condition where the body’s immune system mistakenly attacks its own moisture-producing glands, leading to symptoms like dry mouth and eyes. The treatment being tested is called ianalumab (also known by its code name VAY736), which is a type of medication known as a monoclonal antibody. This medication is designed to target specific parts of the immune system to help reduce the symptoms of the disease. In this study, some participants will receive ianalumab, while others will receive a placebo, which looks like the treatment but does not contain the active medication.

The purpose of the study is to determine if ianalumab is more effective than a placebo in improving the condition of patients with active Sjögren’s syndrome. Participants in the study will receive the treatment or placebo through an injection under the skin, known as a subcutaneous injection, over a period of 52 weeks. Throughout the study, participants will be monitored to assess changes in their symptoms and overall health.

This trial aims to provide valuable information on the safety and effectiveness of ianalumab for treating Sjögren’s syndrome, potentially offering a new option for managing this condition. Participants will be closely observed by healthcare professionals to ensure their well-being and to gather data on how the treatment affects their symptoms over time.

]]> Evaluation of Mesenchymal Stem Cell Eye Injections for Dry Eye Disease in Patients with Graft-versus-Host Disease Who Haven’t Responded to Standard Treatments https://clinicaltrials.eu/trial/evaluation-of-mesenchymal-stem-cell-eye-injections-for-dry-eye-disease-in-patients-with-graft-versus-host-disease-who-havent-responded-to-standard-treatments/ Wed, 29 Apr 2026 15:06:15 +0000 https://clinicaltrials.eu/trial/evaluation-of-mesenchymal-stem-cell-eye-injections-for-dry-eye-disease-in-patients-with-graft-versus-host-disease-who-havent-responded-to-standard-treatments/ This clinical trial is evaluating the effectiveness and safety of Allogeneic Mesenchymal Stem Cell (MSC) eye injections for treating dry eye disease in patients with Graft-versus-Host Disease (GvHD). Graft-versus-Host Disease is a condition that can occur after a bone marrow or stem cell transplant, where the donated cells attack the recipient’s body. When it affects the eyes, it can cause severe dry eye disease, which includes symptoms like eye irritation, burning, and vision problems.

The purpose of this study is to determine if subconjunctival (under the eye’s membrane) injections of stem cells can improve the signs and symptoms of severe dry eye disease that hasn’t responded to conventional treatments. The study will test two different doses of stem cells (6.25 million and 12.5 million) to see which works better.

During the trial, participants will receive ASC (adipose-derived stem cell) injections in their eyes and will be monitored for improvements in various aspects of eye health, including the integrity of the eye surface, tear production, redness of the eye membrane, and function of the oil-producing glands in the eyelids. Researchers will also collect tear and blood samples to analyze inflammation markers and identify potential new ways to track disease improvement.

]]> Study on the Use of PRGF Eye Drops for Treating Dry Eye Disease in Patients https://clinicaltrials.eu/trial/study-on-the-use-of-prgf-eye-drops-for-treating-dry-eye-disease-in-patients/ Wed, 29 Apr 2026 15:05:01 +0000 https://clinicaltrials.eu/trial/study-on-the-use-of-prgf-eye-drops-for-treating-dry-eye-disease-in-patients/ This clinical trial is focused on studying the effects of a new treatment for Dry Eye Disease, a condition where the eyes do not produce enough tears or the tears evaporate too quickly, leading to discomfort and vision problems. The study will test the effectiveness and safety of eye drops made from Plasma Rich in Growth Factors (PRGF), which are derived from blood and contain substances that may help heal and protect the eye surface. These eye drops will be compared to standard artificial tear eye drops containing hypromellose, a common ingredient used to relieve dry eyes.

The purpose of the study is to evaluate how well the PRGF eye drops work and how safe they are for people with dry eye disease. Participants will use the eye drops four times a day for 12 weeks. During this time, they will have regular check-ups to monitor their eye health and any changes in their symptoms. The study will also include a comparison with a placebo to better understand the effects of the PRGF eye drops.

Throughout the study, participants will be asked to complete questionnaires about their symptoms and any side effects they experience. The study aims to provide valuable information on whether PRGF eye drops can offer a better treatment option for those suffering from dry eye disease compared to existing artificial tear solutions. The trial is expected to continue until 2027, with recruitment starting in 2025.

]]> Study on the Effectiveness of PRGF Eye Drops for Treating Dry Eye in Glaucoma Patients https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-prgf-eye-drops-for-treating-dry-eye-in-glaucoma-patients/ Wed, 29 Apr 2026 15:02:34 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-prgf-eye-drops-for-treating-dry-eye-in-glaucoma-patients/ This clinical trial is focused on studying two eye conditions: glaucoma and dry eye disease. The treatment being tested is called Plasma rich in growth factors, which is used in the form of eye drops. These eye drops contain a special substance known as platelet concentrate, which is derived from blood and is believed to help with healing and reducing symptoms of dry eyes.

The purpose of the study is to evaluate how effective these eye drops are in relieving symptoms of dry eye disease in patients who also have glaucoma. Participants in the study will be randomly assigned to receive either the Plasma rich in growth factors eye drops or a different preservative-free eye drop formulation. The study is designed to be double-blind, meaning neither the participants nor the researchers will know which treatment each participant is receiving, to ensure unbiased results.

Throughout the study, participants will use the eye drops for a period of up to 12 months. During this time, they will have regular check-ups to monitor changes in their eye condition, such as the degree of eye dryness and any improvements in symptoms. The study will also assess the safety of the treatment by keeping track of any side effects experienced by the participants. The goal is to determine if the Plasma rich in growth factors eye drops can provide a safe and effective treatment option for people suffering from dry eye disease alongside glaucoma.

]]> Study on the Use of PRGF and Hypromellose Eye Drops for Treating Dry Eye Disease in Patients https://clinicaltrials.eu/trial/study-on-the-use-of-prgf-and-hypromellose-eye-drops-for-treating-dry-eye-disease-in-patients/ Wed, 29 Apr 2026 15:00:14 +0000 https://clinicaltrials.eu/trial/study-on-the-use-of-prgf-and-hypromellose-eye-drops-for-treating-dry-eye-disease-in-patients/ This clinical trial is focused on studying Dry Eye Disease, a condition where the eyes do not produce enough tears or the tears evaporate too quickly, leading to discomfort and vision problems. The study will evaluate the use of PRGF eye drops, which stands for Plasma Rich in Growth Factors, a treatment derived from blood components that may help in healing and reducing inflammation. The trial will compare the effectiveness and safety of these eye drops with artificial tear eye drops containing hypromellose, a substance that helps to lubricate the eyes.

The purpose of the study is to assess whether PRGF eye drops are more effective than artificial tears in treating Dry Eye Disease. Participants will be randomly assigned to receive either the PRGF eye drops or the artificial tear eye drops. The study will last for 12 weeks, during which participants will use the eye drops four times a day. Throughout the study, participants will have regular check-ups to monitor their eye health and any changes in their symptoms.

In addition to the main treatments, some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments. The study aims to provide valuable information on the safety and effectiveness of these treatments for Dry Eye Disease, potentially leading to better management options for those affected by this condition.

]]> Study on the Effects of Ianalumab in Adults with Rheumatoid Arthritis, Systemic Lupus Erythematosus, or Sjögren’s Disease https://clinicaltrials.eu/trial/study-on-the-effects-of-ianalumab-in-adults-with-rheumatoid-arthritis-systemic-lupus-erythematosus-or-sjogrens-disease/ Wed, 29 Apr 2026 14:59:22 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-ianalumab-in-adults-with-rheumatoid-arthritis-systemic-lupus-erythematosus-or-sjogrens-disease/ This clinical trial is focused on studying the effects of a medication called ianalumab in adults with autoimmune diseases, specifically Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Sjögren’s Disease. Autoimmune diseases occur when the body’s immune system mistakenly attacks its own tissues. The study aims to compare how the body processes ianalumab when given in different forms, such as a pre-filled syringe or an auto-injector. Ianalumab is a type of protein-based medication designed to help manage these conditions by targeting specific parts of the immune system.

Participants in the study will receive ianalumab through subcutaneous injections, which means the medication is administered under the skin. The study will take place over a period of time, allowing researchers to observe how the medication is absorbed and processed by the body. The goal is to ensure that the different forms of administering ianalumab are equally effective and safe for patients. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of ianalumab.

In addition to ianalumab, the study will also involve other medications such as emtricitabine, tenofovir disoproxil, tenofovir alafenamide, and entecavir, which are typically used to manage viral infections. These medications will be administered orally, meaning they are taken by mouth. The study will monitor various health indicators, including any side effects, to ensure the safety and effectiveness of the treatments. The overall purpose is to gather information that could lead to better treatment options for people with these autoimmune diseases.

]]> Study on the Safety and Effectiveness of Cenegermin Eye Drops for Patients with Dry Eye Disease https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-cenegermin-eye-drops-for-patients-with-dry-eye-disease/ Wed, 29 Apr 2026 14:30:12 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-cenegermin-eye-drops-for-patients-with-dry-eye-disease/ This clinical trial is focused on studying Dry Eye Disease, a condition where the eyes do not produce enough tears or the tears evaporate too quickly, leading to discomfort and vision problems. The study will test a new treatment using eye drops containing Recombinant Human Nerve Growth Factor (rhNGF) at two different concentrations. These eye drops are designed to help improve the symptoms of dry eye by promoting healing and reducing inflammation in the eyes.

The purpose of the study is to evaluate the safety and effectiveness of these new eye drops compared to a placebo, which is a substance with no active medication. Participants will be randomly assigned to receive either the rhNGF eye drops or the placebo. The study will last for a total of eight weeks, with the first four weeks involving the use of the eye drops and the following four weeks for observation and follow-up. During the study, participants will have regular check-ups to monitor their eye health and any changes in their symptoms.

In addition to the rhNGF eye drops, the study will also use other substances like Fluorescein Sodium, Calcium Chloride, Potassium Chloride, Sodium Chloride, and Tropicamide for various assessments and procedures. These substances are commonly used in eye examinations to help doctors see the surface of the eye more clearly and to measure tear production. The study aims to determine if the new eye drops can provide better relief from dry eye symptoms compared to the placebo, ultimately improving the quality of life for those affected by this condition.

]]> Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ianalumab-for-patients-with-active-sjogrens-syndrome-2/ Wed, 29 Apr 2026 14:27:32 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ianalumab-for-patients-with-active-sjogrens-syndrome-2/ This clinical trial is focused on studying the effects of a treatment for Sjögren’s syndrome, a condition where the body’s immune system mistakenly attacks its own moisture-producing glands, leading to symptoms like dry mouth and eyes. The treatment being tested is called ianalumab, also known by its code name VAY736. It is administered as a solution for injection using a pre-filled syringe. The study also includes a comparison with a placebo, which is a substance with no active medication, to evaluate the effectiveness of ianalumab.

The purpose of the study is to assess how well ianalumab works and how safe it is for patients with active Sjögren’s syndrome. Participants in the study will be randomly assigned to one of three groups: one receiving ianalumab, one receiving a placebo, and another group receiving a standard treatment known as glucocorticoids, which are a type of steroid medication taken orally. The study will last for a total of 52 weeks, during which participants will receive regular injections and have their health monitored closely by the research team.

Throughout the study, the main focus will be on changes in the participants’ health, particularly looking at the ESSDAI score, which is a measure used to assess disease activity in Sjögren’s syndrome. The study aims to demonstrate whether ianalumab is more effective than the placebo in improving this score over the course of the study. Participants will also be monitored for any side effects or changes in their condition to ensure the treatment’s safety and tolerability.

]]> Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome https://clinicaltrials.eu/trial/study-on-long-term-safety-and-efficacy-of-ianalumab-for-patients-with-sjogrens-syndrome/ Wed, 29 Apr 2026 14:26:35 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-and-efficacy-of-ianalumab-for-patients-with-sjogrens-syndrome/ This clinical trial is focused on studying the long-term safety and effectiveness of a treatment called ianalumab for patients with Sjögren’s syndrome. Sjögren’s syndrome is an autoimmune disease where the body’s immune system mistakenly attacks its own moisture-producing glands, leading to symptoms like dry mouth and dry eyes. The study involves the use of ianalumab, which is administered as a solution for injection. Participants in the study may also receive a placebo, which is a substance with no active medication, to compare the effects of the treatment.

The purpose of the study is to assess how well ianalumab works over a long period and to monitor any side effects that may occur. Participants will be randomly assigned to receive either ianalumab or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not biased. The study will continue for several years, allowing researchers to gather comprehensive data on the treatment’s safety and effectiveness.

Throughout the study, participants will have regular check-ups to monitor their health and any changes in their condition. Blood samples will be taken to measure the levels of ianalumab in the body and to check the number of B-cells, which are a type of immune cell. The study aims to provide valuable information on the potential benefits of ianalumab for people living with Sjögren’s syndrome, contributing to better treatment options in the future.

]]> Study on Insulin Eye Drops for Treating Dry Eye in Patients Using Topical Hypotensors https://clinicaltrials.eu/trial/study-on-insulin-eye-drops-for-treating-dry-eye-in-patients-using-topical-hypotensors/ Wed, 29 Apr 2026 14:23:01 +0000 https://clinicaltrials.eu/trial/study-on-insulin-eye-drops-for-treating-dry-eye-in-patients-using-topical-hypotensors/ This clinical trial is focused on studying the effects of a new treatment for dry eye disease, a condition where the eyes do not produce enough tears or the tears evaporate too quickly, leading to discomfort and vision problems. The study will test the use of insulin eye drops to see if they can help manage dry eye symptoms in patients who are already using medications called topical hypotensors, which are often used to treat conditions like ocular hypertension or glaucoma. The trial will compare the effects of insulin eye drops to a placebo, which in this case is artificial tears.

The purpose of the study is to evaluate how effective and safe insulin eye drops are in controlling dry eye disease. Participants will be asked to use the eye drops over a period of six months. During this time, researchers will monitor changes in symptoms and other eye health indicators, such as corneal staining, which is a test to check for damage on the surface of the eye, and conjunctival hyperemia, which refers to redness of the eye. The study will also look at how well the tear film, the thin layer of fluid covering the eye, holds together over time.

Throughout the study, participants will have regular check-ups to assess their eye health and any changes in their condition. The trial will also track any side effects experienced by participants and how well they adhere to their existing hypotensive treatment. The study aims to provide valuable information on whether insulin eye drops can be a beneficial treatment option for those suffering from dry eye disease while using topical hypotensors.

]]> Study on the Effectiveness and Safety of Insulin, Ciclosporin, and Benzalkonium Chloride in Patients with Moderate to Severe Dry Eye Disease https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-insulin-ciclosporin-and-benzalkonium-chloride-in-patients-with-moderate-to-severe-dry-eye-disease/ Wed, 29 Apr 2026 14:22:57 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-insulin-ciclosporin-and-benzalkonium-chloride-in-patients-with-moderate-to-severe-dry-eye-disease/ This clinical trial is focused on studying the effectiveness and safety of using insulin eye drops for treating dry eye disease. Dry eye disease is a common condition where the eyes do not produce enough tears or the tears evaporate too quickly, leading to discomfort and vision problems. The study will explore whether insulin, a hormone commonly used to manage blood sugar levels in diabetes, can help control moderate to severe cases of this eye condition when applied as eye drops.

Participants in the study will receive either the insulin eye drops or a placebo for a period of six months. The study will also involve the use of artificial tears, which are eye drops that help to lubricate the eyes, and ciclosporin, a medication that can reduce inflammation in the eyes. The aim is to see if insulin eye drops can improve symptoms and eye health compared to these other treatments.

Throughout the study, changes in eye health will be monitored, including improvements in symptoms and any side effects experienced by participants. The goal is to determine if insulin eye drops can be a safe and effective treatment option for those suffering from dry eye disease. Participants will be regularly assessed to track their progress and any changes in their condition over the course of the study.

]]> Study on the Effectiveness and Safety of Hydrocortisone Sodium Phosphate for Patients with Dry Eye and Moderate Meibomian Gland Dysfunction https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-hydrocortisone-sodium-phosphate-for-patients-with-dry-eye-and-moderate-meibomian-gland-dysfunction/ Wed, 29 Apr 2026 14:22:53 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-hydrocortisone-sodium-phosphate-for-patients-with-dry-eye-and-moderate-meibomian-gland-dysfunction/ This clinical trial is focused on studying the effects of a treatment for Dry Eye Disease associated with moderate Meibomian Gland Dysfunction. The treatment being tested includes the use of eye drops containing hydrocortisone sodium phosphate, which is a type of medication that helps reduce inflammation. The study will also involve the use of lid hygiene practices, artificial tears, and a medical device called the BlephaEyeBag, which is a reusable eye bag that can be heated in a microwave.

The purpose of the study is to evaluate the effectiveness and safety of this treatment combination. Participants will be monitored over a period of time to observe changes in their symptoms and any potential side effects. The study will track changes in symptoms from the start of the study to two weeks later, and will also look at the levels of certain proteins in tears that are related to inflammation. Additionally, the study will monitor the pressure inside the eyes at various points to ensure safety.

Participants will be asked to follow the treatment plan and attend several follow-up visits over a few months. During these visits, researchers will assess the symptoms of dry eye and meibomian gland dysfunction, as well as any changes in vision or eye health. The study aims to provide valuable information on how well this treatment works and its safety for people with these eye conditions.

]]>